Clinical trial

A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients

NCT00002178

Study summary

ClinicalTrials.gov

A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Ritonavir Normalized identity: ritonavir View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Nelfinavir mesylate Normalized identity: nelfinavir mesylate View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Saquinavir Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Delavirdine mesylate Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start dateUnknown

PhasePHASE3

Conditions

HIV Infectionsunresolved

Interventions

RitonavirDRUG · verified · RxNorm: ritonavir

Nelfinavir mesylateDRUG · verified · RxNorm: nelfinavir mesylate

SaquinavirDRUG

Delavirdine mesylateDRUG

Sponsors & collaborators

Hoffmann-La Rochelead sponsor

Mapped research locations

Los AngelesCalifornia, United States1 BrooklineMassachusetts, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00002178 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.